More recently, Dehdashti et al. conducted a phase II trial in 43 women with postmenopausal advanced ER-positive breast cancer, to explore the hypothesis that a brief estradiol challenge would increase tumor expression of the PgR only in patients with a functional ER. This evidence concerns the gene ESR1 and neoplasm.